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The use of aptamers in biosensing have gained considerable attention as an attractive 16 
alternative to antibodies because of their unique properties such as long term stability, cost 17 
effectiveness and tunability to various applications. Among various cancers, early diagnosis 18 
of prostate cancer (PCa) is one of the biggest concerns for ageing men worldwide. One of the 19 
most commonly used biomarker for PCa is prostate specific antigen (PSA), which can be 20 
found in elevated levels in patients with cancer. In this review, a presentation on the gradual 21 
transition of research from antibody-based to aptamer-based biosensors is presented 22 
specifically for PSA. A brief description on aptamer-based biosensing for other PCa 23 
biomarkers is also presented. Special attention is given to electrochemical methods as 24 
analytical techniques for development of simple, sensitive and cost effective biosensors. The 25 
review also focuses on different surface chemistries exploited for fabrication and their 26 
application with clinical samples. Utilization of aptamers provides a promising tool for 27 
development of point-of-care biosensors for early detection of prostate cancer. In the view of 28 
the unmatched upper hand of aptamers, future perspectives are also discussed, not only in the 29 
point of care format but also in other novel applications. 30 
 31 
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Introduction 36 
 37 
Prostate cancer (PCa) is a type of cancer that develops in the prostate gland, which is a 38 
part of a male reproductive system. PCa is the most commonly diagnosed cancer amongst 39 
men in Europe and the United States and is the second worldwide leading cause of morbidity. 40 
It has been reported that PCa is predominant in older men above the age of 50 (Kirk, 1997; 41 
Hoffman, 2011) and among black men (Stanford et al., 1999; Greenlee et al., 2000). It has 42 
been also projected that PCa will be the most common cancer by 2030 in the UK (Greenlee et 43 
al., 2000; Jeong et al., 2010). 44 
Most of the PCa generate in the epithelium cells (Bostwick, 1989). As androgens 45 
regulate cell division of the gland epithelium (Ross et al., 1998), these hormones are believed 46 
to be the main cause of PCa. However, a study demonstrating a consistent correlation between 47 
androgens and prostatic carcinogenesis has not yet been reported to date and the precise 48 
causes that lead to PCa are still not well understood (Kufe et al., 2003). 49 
PCa often develops very slowly and the lack of symptoms during the early stages of 50 
the disease leads to a late diagnosis of the tumour. Moreover, if diagnosed at a late stage, no 51 
effective treatments are currently available for its cure. In many cases PCa does not show any 52 
clinical manifestation during the lifetime of a patient, who might die for non-related PCa 53 
causes. However, for those patients that develop a more aggressive cancer form, PCa cells can 54 
break away from a prostate tumour and metastasise. Since the prostate is well connected to 55 
numerous lymph nodes, the spread is easy and some of the most common sites of PCa 56 
metastatic process are bones (Chou & Simons, 1997). 57 
 58 
 59 
Current detection methods 60 
 61 
There is no solitary test for the diagnosis of PCa. Moreover, all the tests which are 62 
used to diagnose have pros and cons which are usually discussed by the doctors with their 63 
patients. The most commonly used methods for PCa detection are: digital rectal examination 64 
(DRE), transrectal ultrasound (TRUS), biopsy and PSA blood test. 65 
In DRE, a doctor inserts a gloved finger into the rectum and examines for bumps or 66 
swelling of the prostate gland. It is an inexpensive method and can also detect PCa 67 
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irrespective of changes in the level of prostate specific antigen (PSA) in blood. Accuracy of 68 
diagnosis can be increased when DRE is combined with PSA tests and biopsy results (Uzzo et 69 
al., 1995; Basler & Thompson, 1998; Jeong et al., 2010). In comparison to DRE, in the TRUS 70 
method an ultrasound probe is inserted into the rectum, emitting energy sound waves to image 71 
the prostate gland. It is a very useful tool to understand pathology of tumours and in guiding 72 
needle biopsies for sampling of tissue (Aus et al., 1996; Irani et al., 1997). For a biopsy, a 73 
small section of the tissue is removed through the rectum using a needle and is 74 
microscopically examined by pathologists. It requires a high number of samples from the 75 
prostate making it a painful protocol. Not only the results from biopsies are controversial, 76 
there is also a high risk of severe infections with subsequent biopsies (Jeong et al., 2010; Loeb 77 
et al., 2013). 78 
The most frequently used test for PCa screening is the quantification of levels of PSA 79 
in blood. If PSA levels are higher than the cut off levels of 4 ng/ml, biopsy procedures are 80 
considered (Catalona et al., 1991, Jeong et al., 2010; Savory et al., 2010). However, the levels 81 
of PSA in blood in ageing men can also be raised due to other factors like benign prostatic 82 
hyperplasia (BPH) and prostatis, which could lead to an over-diagnosis in men (Carter et al., 83 
1992). Consequently, due to faulty diagnosis, patients undergo biopsy surgery making PSA 84 
testing a controversial diagnostic tool. Due to these controversies with PSA testing, in May 85 
2012 the US Preventative Services Task Force recommended against PSA screening in all 86 
men. This emphasized the need for more reliable biomarkers for diagnosis of the disease 87 
(Moyer, 2012). 88 
 89 
 90 
Prostate specific antigen (PSA): a PCa biomarker 91 
 92 
PSA belongs to the family of kallikrein proteins which are defined as serine proteases. 93 
There are about 15 kallikrein family members that have been identified in humans. PSA is the 94 
only kallikrein specific to prostate (hK3). Pancreatic renal kallikrein (hK1) and human 95 
glandular kallikrein (hK2), which are androgen regulated, are also expressed in the prostate 96 
(Balk et al., 2003).  97 
PSA is synthesised in its inactive form: a 244 amino acid long protein called pro-PSA. 98 
Pro-PSA is cleaved from the N terminus in the prostate by the hK2 enzyme leading to active 99 
PSA which is a 237 amino acid long protein (Takayama et al., 1997). The active PSA is a 100 
30 kDa protein which can be found in both serum and semen of men. PSA is present in semen 101 
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in the range of 0.5 - 2 mg/ml and its physiological role is to de-coagulate semen by breaking 102 
down the proteins semenogelin I and II (Lilja et al., 1987; Lövgren et al., 1999). In prostate 103 
cancer there is release of both active PSA and pro-PSA due to rupture of the basal membrane. 104 
Moreover, internally cleaved forms of PSA (with no enzymatic activity) also enter the blood 105 
stream but remain un-complexed and are taken into the free PSA (fPSA) count. However, 106 
when active PSA enters the blood stream it becomes immediately complexed with protein 107 
inhibitors. Most of the assays employing antibodies measure the total amount of PSA (tPSA) 108 
(Takayama et al., 1997).  109 
Many studies reported that PSA levels are directly proportional to the stage of the 110 
cancer and to the volume of the tumour (Stamey et al., 1987; Grossklaus et al., 2002; Pinsky 111 
et al., 2007; Lilja et al., 2008). PSA detection results are nowadays highly sensitive (Madu & 112 
Lu, 2010) and reasonably inexpensive. Moreover PSA testing is a more accepted procedure 113 
by patients compared to DRE and this has augmented the early detection of PCa (Balducci et 114 
al., 1997). However, even though PSA testing induced a decrease in PCa mortality of 20% its 115 
screening led to over-diagnosis and over-treatment (Andriole et al., 2009) of patients that 116 
would have not been clinically affected by the tumour during their lifetime. Over diagnosis 117 
can, in fact, lead to unnecessary treatments and increase the state of anxiety in patients. 118 
Conversely, clinicians are not able nowadays to discriminate between a harmless or lethal 119 
form of prostate cancer and so to decide whether the patient needs a treatment. Once a 120 
prostate cancer has been definitively treated, PSA screening is the most reliable and fast 121 
means that enable to detect a contingent recurrence of the tumour (Lilja et al., 2008). 122 
With the shortcomings of the current tests for PCa, including PSA testing, there is a 123 
concerted effort to look for alternatives. However, it would be a challenge to replace PSA 124 
entirely due to its minimally invasive nature and low cost. Instead, there is a pressing need to 125 
look for other biomarkers to complement PSA that can increase the specificity and sensitivity 126 
of PCa screening and inform prognosis and treatment courses.  127 
One path currently being looked at when a high level of PSA is detected in patients 128 
with cancer, is to differentiate PSA into different forms namely free PSA (fPSA) and total 129 
PSA (tPSA) and quantify them independently. One of the approaches is to measure the ratio 130 
of free PSA to total PSA in the blood. It has been proven, in fact, that the levels of fPSA are 131 
lower in patients with PCa than in patients with BPH (Christensson et al., 1993), which can 132 
thus be an indication of the aggressiveness of the cancer. However, the method can cause 133 
false negative results as the amount of fPSA can be higher in patients with larger prostate 134 
volume (Stephan et al., 1997; Catalona et al., 1998). Nevertheless, the ratio of free to total 135 
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PSA when combined with the total PSA levels increases the confidence of the diagnosis 136 
(Velonas et al., 2013). 137 
 138 
Pro-PSA 139 
Several studies are also focused on the detection of a distinct form of free PSA, called 140 
proenzyme PSA (pro-PSA). Pro-PSA is an enzymatically inactive precursor of PSA obtained 141 
by co-translational removal of an amino-terminal leader. The N-terminal of pro-PSA can be 142 
cleaved at various positions resulting in different forms of pro-PSA. Pro-PSA truncated 143 
between the third and second amino acid is called [-2]pro-PSA and is believed to provide a 144 
better discrimination between cancerous and benign form of prostate disorders (Mikolajczyk 145 
et al., 2001; Mikolajczyk et al., 2004). Increased values of other forms of pro-PSA ([-5] and 146 
[-7]) have also been associated to PCa. A truncated precursor form of prostate-specific 147 
antigen is therefore a more specific serum marker of prostate cancer.  148 
 149 
PSA density 150 
A better discrimination of BPH from PCa might be achieved by measuring the ratio of 151 
PSA to prostate volume. However, this parameter called PSA density showed contradictory 152 
evidence on the tumour aggressiveness and malignity (Stamey et al., 1987; Ohori et al., 153 
1995). Furthermore, in order to obtain prostate volume values, TRUS is required in addition 154 
to the standard PSA test with a consequent discomfort for patients as well as an increase in 155 
the cost and time required to perform the test. For these reasons PSA density has not been 156 
extensively employed as a routine test for PCa. 157 
 158 
PSA velocity and PSA doubling time 159 
PSA velocity refers to the rate of serum PSA increase over time while PSA double 160 
time refers to the time required for a given PSA level to be doubled. As the previous PSA 161 
derivatives, also PSA velocity can be used to distinguish a prostate cancer from a BPH (Carter 162 
et al., 1992). Both PSA velocity and PSA double time are used to monitor the recurrence of 163 
the tumour after treatment (D'Amico et al., 2004; D'Amico et al., 2005). Again, some studies 164 
compared the responses from PSA velocity and PSA double time with biopsy results 165 
demonstrating how these two PSA derivatives can fail the diagnosis (Melichar, 2012) 166 
 167 
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Age-specific PSA reference ranges 168 
Since the level of PSA increases with the age of men, scientists studied this correlation 169 
in order to obtain a median value of PSA for given ranges of age. By comparing the PSA 170 
level with the median PSA for that patient’s age (age-specific PSA) a better choice might 171 
been taken before ordering biopsies (Loeb & Catalona, 2007). 172 
 173 
 174 
Oligonucleotide Aptamers 175 
 176 
In recent years, a range of assays for PSA detection such as electrochemical assays 177 
(Okuno et al., 2007; Panini et al., 2008), enzyme linked immunosorbent assays (Acevedo et 178 
al., 2002), cantilever assays (Wee et al., 2005), and chemiluminescent immunoassays 179 
(Albrecht et al., 1994; Seto et al., 2001) have been developed. These assays are mostly based 180 
on antibodies as recognition elements. One of the alternatives to antibodies is aptamers which 181 
can offer several advantages with respect to the former. However, an enormous research is 182 
being carried out to prove if antibodies can be replaced by aptamers to develop a real 183 
biosensor for clinical applications. The scope of this review is to highlight the major 184 
developments on PSA aptasensors and their potential to be used with real clinical blood 185 
samples. 186 
Oligonucleotide aptamers are single stranded DNA or RNA sequences that can bind to 187 
a target molecule with high specificity and affinity. Aptamers had already been widely used in 188 
drug delivery applications and are now being extensively studied as new emerging 189 
bioreceptors for biosensors (termed aptasensors) (Hianik & Wang, 2009; Iliuk et al., 2011). 190 
Aptamers have shown comparable or even stronger binding than antibodies towards a broad 191 
range of targets (e.g. proteins, peptides, amino acids, drugs, whole cells, etc.), especially with 192 
the development of novel selection technologies (Xiao et al., 2005). The high affinity of the 193 
aptamers towards the target molecule is defined by their capability of undergoing 194 
conformation changes upon the binding event (Hermann & Patel, 2000; Song et al., 2008; 195 
Hianik & Wang, 2009). Although using aptamers have many added advantages over 196 
antibodies, they still need careful consideration while fabricating a biosensor. For instance, 197 
binding of an aptamer to protein might be affected by changing buffer conditions. Also, as 198 
aptamers are oligonucleotide sequences, special care is needed as they are sensitive to DNase 199 
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and RNase activity. Furthermore, the kd value of aptamers is often not as good as that for 200 
antibodies.  201 
Aptamers are developed using an in vitro selection process based on Systematic 202 
Evolution of Ligands by EXponential enrichment (SELEX) (see fig. 1). Briefly, it consists of 203 
three steps that are repeated systematically in order to identify the oligonucleotide sequence 204 
that binds better to the target. The first step is called library generation, where a library 205 
consisting of random DNA or RNA sequences (usually 30-40 base-pairs long) flanked by the 206 
primer binding site are used. The library is then incubated with the target molecule. 207 
Thereafter, the target bound library is separated from unbound library. Finally, the target-208 
bound library is amplified using polymerase chain reaction (PCR) to create a new library to be 209 
used in the next round. Aptamers binding and conformation characteristics are identified 210 
using various biological assays (Syed & Pervaiz, 2010; Liu et al., 2012). 211 
 212 
 213 
 214 
 215 
Fig. 1. The general SELEX protocol. Starting with a random library followed by incubation 216 
with the target. Later the bound sequences are separated and further amplified for the 217 
next round of selection. Adapted from Song et al. (2008). 218 
 219 
 220 
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There has been an intense interest in understanding the in-depth of ligand-binding and 221 
conformational properties of aptamers. Aptamers have many advantages over antibodies, 222 
making them very important molecular tools for both diagnostics and therapeutics. For 223 
instance, selection of aptamers is an in vitro process and they can be raised to a wide variety 224 
of targets ranging from small molecules and toxins to large proteins and even whole cells. 225 
Secondly, aptamers, once selected, can be synthesised with high purity and reproducibility. 226 
Also, as compared to antibodies, aptamers are usually highly chemically stable. Furthermore, 227 
they can undergo significant conformational changes in their structure upon binding with the 228 
target – a feature which can be exploited for biosensing applications. This offers great 229 
flexibility to design novel biosensors (Clark & Remcho, 2002; Tombelli et al., 2005; Willner 230 
& Zayats, 2007; Mairal et al., 2008; Song et al., 2008; Liu et al., 2012). 231 
 232 
 233 
PSA detection 234 
 235 
PSA is currently detected in dedicated laboratory settings using automated analysers 236 
running antibody-based assays which are generally expensive and time consuming (Lin & Ju, 237 
2005; Healy et al., 2007). Cost effective, easy to use and possibly portable devices are 238 
required in order to allow more powerful tools for early detection of prostate cancer. To date, 239 
researchers have exploited several techniques for PSA detection such as optical (Besselink et 240 
al., 2004; Huang et al., 2005; Cao & Sim, 2007), piezoelectric (Weeks et al., 2003; Wee et al., 241 
2005) and electrochemical (Sarkar et al., 2002; Fernández-Sánchez et al., 2004; Liu et al., 242 
2013). 243 
Although label-free-based biosensors can provide many advantages, label-based 244 
approaches are still intensively studied and can offer interesting features such as low limit of 245 
detection due to amplification strategies. An interesting magnetic bead-based detection system 246 
for PSA detection was developed by Zani et al. (2009): paramagnetic microparticles were 247 
adsorbed on an array of screen-printed electrodes and PSA was sandwiched in between two 248 
antibodies on the beads; the alkaline-phosphatase-labelled secondary antibody could be 249 
detected with differential pulse voltammetry (DPV) to achieve a detection limit of 1.4 ng/ml. 250 
A limit of detection as low as 0.5 pg/ml in undiluted serum samples was obtained by Mani et 251 
al. (2010) by combining a multienzyme-labelled immunoassay with gold nanoparticles 252 
sensing surface: in this case the secondary antibody was bound to micromagnetic HRP-253 
labelled beads, which massively amplified the current signals for a very low PSA detection 254 
 9 
limit. A similar detection technique was improved and integrated in a microfluidic system by 255 
Chikkaveeraiaha et al. (2011) reaching an even lower detection limit. A fascinating 256 
electrochemiluminescence-based immunoassay was developed by Sardesai et al. (2011) for 257 
both PSA and interlukin 6 (IL-6) by using single-wall carbon nanotubes (SWCNT) fabricated 258 
on microwells and a sandwich assay where the secondary PSA antibody was functionalized 259 
with RuBYP-Silica particles: the detection limit achieved was of 1 pg/ml for PSA. 260 
 261 
Label-free electrochemical sensors for PSA detection 262 
Electrochemical techniques are widely employed in biosensing devices as they can be 263 
highly sensitive, simple to perform and cost effective. An electrochemical biosensor involves 264 
an electrode surface that is functionalised with a molecular recognition element for sensing 265 
biomolecules. Binding of an analyte to this element results in an electrical change in current 266 
transfer (amperometric), voltage (potentiometric and field effect transistors), impedance 267 
(impedimetric), conductivity (conductometric) or ion charge across the electrode, which can 268 
be quantified and correlated to the amount of analyte captured.As mentioned in the previous 269 
sections, most biosensors for PSA detection currently available are antibody-based. Amongst 270 
the antibody-based electrochemical sensors, particularly important results are the ones using 271 
label-free systems. Arya & Bhansali (2012) developed a gold biosensor modified with a 272 
cysteamine self-assembled monolayer (SAM) for PSA detection. Li et al. (2005), on the hand, 273 
employed In2O3 nanowires and carbon nanotubes. Electrochemical impedance spectroscopy 274 
(EIS) based sensors have been reported by Chiriacò et al. (2013) and Chornokur et al. (2011). 275 
The former exploits a combined use of two different antibodies for both free and total PSA, 276 
while the latter reported on a miniaturized sensor obtained with photolithographic techniques 277 
using a single monoclonal antibody. Another label-free antibody-based sensor which uses a 278 
polycrystalline silicon field-effect transistor was reported by Huang et al. (2013). 279 
 280 
 281 
Aptasensor for PSA detection 282 
 283 
An aptasensor biosensor comprises an aptamer as a biorecognition element (Lim et al., 284 
2009). Aptasensors can be integrated with different sensing techniques such as 285 
electrochemical, optical, and mass sensitive. Among these varied techniques, electrochemical 286 
aptasensors have been fabricated using several detection techniques, namely EIS, 287 
potentiometry and differential pulse voltammetry (DPV) (Cho et al., 2009; Clark & Remcho, 288 
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2002; Feng et al., 2008; Ikebukuro et al., 2005; Liu et al., 2012; Numnuam et al., 2008; Wang 289 
et al., 2007; Xu et al., 2005). For detection of PSA, both RNA and DNA aptamers have been 290 
developed, although there are only a handful of reports on PSA biosensors using aptamers. A 291 
summary of aptamer-based biosensors for PCa detection is presented in table 1.  292 
 293 
 294 
Table 1. Performance comparison of different aptasensors for PCa detection 295 
 296 
Method Material Biomarker Detection limit Reference 
QCM-D/EIS Gold PSA - Formisano et al., 2014 
EIS Gold PSA 1 ng/ml Jolly et al., 2014 
Optical AuNPs PSA 32 pg/ml Chen et al., 2012  
DPV/CV AuNPs@GMCs PSA 0.25 ng/ml Liu et al., 2012 
EIS Gold PSMA cells - Min et al., 2010 
 297 
 298 
The first aptamer developed was a RNA aptamer (Jeong et al., 2010) that has been 299 
used to demonstrate the recognition of active PSA. Following that, a DNA aptamer was 300 
developed using a genetic algorithm with post-SELEX screening against PSA (Savory et al., 301 
2010). To date, there is no reported literature on the application of RNA aptamers for PSA 302 
biosensing, which could be due to the long length of the sequence making it difficult to 303 
synthesise commercially.  304 
DNA based PSA aptamer has been combined with different sensing techniques with 305 
sensitivities ranging from pg/ml to ng/ml. Chen et al. (2012) were the first to report the use of 306 
PSA aptamer to develop an optical based aptasensor. The conjugation of gold nanoparticles 307 
(AuNPs) with DNA aptamers were used to develop an aptasensor based on resonance light 308 
scattering (RLS) spectral assay. The novel technique relied on changes in resonance light 309 
scattering on binding of PSA to the aptamer, with a detection limit of 32 pg/ml. Thiolated 310 
DNA aptamers were immobilized on AuNPs and then a blocking step with BSA was 311 
performed prior the use of the complex AuNPs-aptamers with PSA samples. In this 312 
configuration, the gold surface of the nanoparticles was covered by the flexible aptamer 313 
structure and as a result no aggregation of particles occurred in absence of PSA. In the 314 
presence of PSA, aptamer-PSA complexes were formed and the aptamers undergo a 315 
conformational change in their structure from flexible to rigid. The changes in aptamer 316 
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conformation exposed some parts of the AuNPs that were thus available to form AuNPs 317 
aggregates upon addition of potassium chloride. This resulted in an increase in the RLS 318 
signal. The assay exhibited good sensitivity and selectivity towards PSA and tests made on 319 
human blood samples showed results comparable to those obtained with ELISA (relative 320 
deviation < 7%). 321 
 322 
 323 
 324 
 325 
Fig. 2. Schematic illustration of fabrication process of the aptasensor based on gold 326 
nanoparticles encapsulated by graphitized mesoporous carbon (a); PSA detection (b). 327 
Adapted from Liu et al. (2012). 328 
 329 
 330 
With regards to electrochemical aptasensor, modification of the electrode surface is 331 
one of the biggest fields of investigation. Research is typically focused on finding the most 332 
suitable recognition platform to give a stable organization to the sensor interface leading to 333 
optimized binding efficiency and signal outcome (Lee et al., 2005; Putzbach & Ronkainen, 334 
2013). Liu et al. (2012) applied aptasensors based on amplification via AuNPs and 335 
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graphitized mesoporous carbon (GMCs) combined with streptavidin-biotin system for 336 
electrochemical detection of PSA (see fig. 2). GMCs encapsulated AuNPs formed the first 337 
layer on cleaned pyrolytic graphite electrode followed by coating with streptavidin. All the 338 
non-specific sites were blocked with bovine serum albumin (BSA). Finally, biotinylated DNA 339 
aptamers were allowed to react with streptavidin immobilized on electrode surface. The 340 
fabricated aptasensor was then used to capture PSA which was measured via differential pulse 341 
voltammetry (DPV). The limit of detection of the aptasensor was 0.25 ng/ml with high 342 
specificity to PSA. In spite of high sensitivity and specificity, the fabrication procedure which 343 
is a layer-by-layer development of sensor surface is quite complex, which may be a drawback 344 
in fabricating a cost effective sensor. The group also used Electrochemical Impedance 345 
Spectroscopy (EIS) to characterize the layer-by-layer fabrication of the aptasensor.  346 
Electrochemical Impedance Spectroscopy is one of the most promising 347 
electrochemical techniques for DNA-based approaches but requires a careful design in order 348 
to optimize its signal. Particularly important for EIS biosensors is the formation of a well-349 
organized self-assembled monolayer (SAM) which allows an optimal charge transfer to occur. 350 
For successful EIS measurements, it is necessary to have a good and reliable SAM layer on 351 
the gold electrode surface. One of the most accepted approaches to achieve this goal is by 352 
alkanethiol chemistry. Alkanethiols can be easily adsorbed and form SAMs (Love et al., 353 
2005) on a clean gold surface through thiol bonds (see fig. 3). It has been reported that longer 354 
alkane chains give a more compact structure with minimal defects (Campuzano et al., 2006). 355 
Among different configuration of SAM, a mixed SAM of 11-Mercaptoundecanoid acid 356 
(MUA), HS(CH2)10COOH, and 6-Mercapto-1-hexanol (MCH), HS(CH2)6OH, exhibited 357 
reasonable starting impedance values and improved reliability (Herne & Tarlov, 1997). In 358 
order to gather or to enhance the extent of a measureable signal of the recognition event 359 
occurring on the working electrode, marker molecules such as redox couples, are exploited. 360 
The recognition events that happen on the SAM not only modify the charge transfer processes 361 
between redox couples present in the measurement solution and the sensor surface but also 362 
affect the double layer at the sensor interface. Both these events cause a change in the system 363 
charge transfer resistance (Rct) which can then be measured by using an appropriate 364 
equivalent circuit. 365 
 366 
 367 
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 368 
 369 
Fig. 3. Schematic illustration of fabrication process of the aptasensor with 6-mercaptohexanol 370 
and thiolated DNA aptamer.  371 
 372 
 373 
In EIS measurements using PSA aptamers, Jolly et al. (2014) and Formisano et al. 374 
(2014) reported a reduction in charge transfer resistance (Rct) upon binding of PSA to the 375 
immobilised DNA aptamers. This decrease is contradictory to what has been reported in the 376 
literature for PSA where an increase of Rct has been observed (Liu et al., 2012), even though 377 
these studies used EIS mainly to characterize the bio-recognition layer and not for dose 378 
response determination. A reduction of Rct upon aptamer-analyte interaction has also been 379 
reported for a different aptasensor using a lysozyme aptamer, where the reduction in charge 380 
transfer resistance upon binding of lysozyme to its specific DNA aptamer was attributed 381 
mainly due to screening of charges on DNA (Rodriguez et al., 2005). The reduction of Rct 382 
could arise from two reasons: firstly, upon binding, PSA might screen the charges of the DNA 383 
aptamer; secondly, as PSA is also a charged protein, it could be that more positive charges are 384 
exposed because of the protein architecture itself. Consequently, as there is screening of 385 
charges of DNA, there is a reduction on electrostatic barrier to the ferro/ferricyanide anions 386 
towards the electrode surface, leading to lowering of the Rct value of the system. 387 
Earlier reports on DNA detection using DNA (Keighley et al., 2008a) and PNA probes 388 
(Keighley et al., 2008b) have demonstrated the importance of optimization of the 389 
oligonucleotide probe surface coverage in order to have efficient binding. On the same 390 
grounds, Formisano et al. (2014) investigated for the first time the importance of optimization 391 
of surface coverage by DNA aptamer for efficient binding using Quartz Crystal Microbalance 392 
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with Dissipation mode (QCM-D). The aim of this study was to optimize the conditions of an 393 
EIS aptamer-based sensor for PSA detection. In fact, EIS optimisation for DNA aptamers is 394 
somewhat complex due to the different characteristics that induce a signal change: namely 395 
DNA density, change in charge density close to the electrode upon DNA conformational 396 
changes, size and charge of the analyte, screening of DNA charges upon analyte binding. The 397 
use of QCM-D provided valuable information about conditions for maximum analyte binding 398 
as well as the hydration, folding and behaviour of the aptamer distribution on the electrode. 399 
The system comprised a gold surface functionalized with a mixed SAM made of DNA 400 
aptamer and MCH which was used as spacer molecule. The best conditions in terms of buffer 401 
solution and aptamer mole fraction (concentration of aptamers/total thiols) for the binding of 402 
PSA to the aptamers were obtained by comparing the data from two techniques under similar 403 
conditions. With regards to the buffer conditions, the study demonstrated how the DNA 404 
aptamers’ behaviour exhibits a strong dependence on the environment where it interacts with 405 
PSA.  406 
In order to investigate an optimum surface chemistry that not only has a good 407 
antifouling effect but is also simple and cost effective, a new molecule has been investigated 408 
by Jolly et al. (2014) as a spacer molecule replacing MCH: a thiol terminated sulfo-betaine 409 
(fig 4). It was the first report on thiol terminated sulfo-betaine application for aptamer-based 410 
sensor. Thiol terminated sulfo-betaine, which has a molecular mass of 398.6 g/mole, is a 411 
zwitter ion due to presence of both positive and negative charges with a flexible chain that 412 
makes it a good antifouling molecule (see Fig 5). It been reported that sulfo-betaine not only 413 
reduces non-specific binding but also increases the sensitivity of the sensor (Bertok et al., 414 
2013). 415 
 416 
 417 
 418 
 419 
Fig. 4. Structure of thiol terminated sulfo-betaine. Image adapted from Bertok et al. (2013). 420 
 421 
 422 
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 423 
 424 
Fig. 5. Schematic of fabrication of thiol terminated sulfo-betaine based PSA aptasensor. (a) 425 
First SAM layer by co-immobilizing 11-mercatoundecanoic acid with thiol terminated 426 
sulfo-betaine. Image adapted from Jolly et al. (2014). 427 
 428 
 429 
A comparison study between MCH and thiol terminated sulfo-betaine thiol chemistry 430 
was carried out by monitoring non-specific binding using human serum albumin (HSA) as a 431 
control protein. A schematic of the fabrication protocol for surface chemistry with thiol 432 
terminated sulfo-betaine is presented in fig 5. Co-immobilization of 11-mercaptoundecanoic 433 
acid (MUA) and thiol terminated sulfo-betaine formed the first SAM layer on clean gold 434 
electrodes. The carboxyl group of MUA was then activated with conventional EDC/NHS 435 
coupling reaction. The activated carboxyl groups were then used to immobilize amine 436 
terminated DNA aptamers for PSA and finally the electrodes were treated with ethanolamine 437 
to deactivate all the unreacted groups. The fabricated aptasensor with thiol terminated sulfo-438 
betaine surface chemistry can discriminate PSA levels down to 1 ng/ml, which falls in the 439 
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lower clinical cut-off range of PSA in blood. The fabricated aptasensor with thiol terminated 440 
sulfo-betaine also showed a significant reduction of the non-specific binding with HSA as 441 
compared to the sensor where MCH was used instead as a spacer molecule. However, it has 442 
also been reported the obstacles on the optimization of the amount of DNA aptamers 443 
immobilized on the surface via EDC/NHS coupling. It was assumed that the charged thiol 444 
terminated sulfo-betaine has an influence on the attachment of DNA aptamer to activated 445 
MUA via EDC/NHS coupling leading to difference in amounts of DNA aptamers in different 446 
electrodes fabricated under similar conditions. 447 
 448 
 449 
Aptasensors for other PCa biomarkers 450 
 451 
Besides PSA, other biomarkers for PCa are currently studied and can potentially be 452 
used for DNA/RNA-based detection systems. One is the prostate-specific membrane antigen 453 
(PSMA), which is a type II integral membrane glycoprotein found in human serum. It is 454 
overexpressed on prostate tumour cells and may play an important role in the progression of 455 
PCa. It can also differentiate between BPH and PCa (Feneley et al., 2000; Ghosh and Heston, 456 
2004; Madu and Lu, 2010; Pircher et al., 2011). Furthermore, by analysing the expression of 457 
PSMA, two cell lines can be distinguished among PCa cells: PSMA (-) and PSMA (+) cells 458 
(Ghosh and Heston, 2004). Min et al. (2010) reported on an RNA/peptide dual-aptamer-based 459 
biosensor able to detect both PSMA (-) and PSMA (+) cells by using EIS. The biosensor 460 
comprises of an anti-PSMA RNA aptamer (Lupold et al., 2002) which can target PSMA (+) 461 
cells and a DUP-1 peptide aptamer (Zitzmann et al., 2005) specific for PSMA (-) cells. 462 
Another emerging biomarker is Alpha-methylacyl-CoA Racemase (AMACR), which 463 
is a racemace type of protein found in urine and blood. Its function is to metabolize fatty acids 464 
in the human body. It is also overexpressed in PCa and can be detected with a high sensitivity 465 
and specificity with a cut off value of 10.6 ng/ml. It also has the potential to differentiate 466 
between BPH and PCa. Currently AMACR aptamers have been independently developed by 467 
Base Pair Biotechnologies, Inc. (aptamer AM310_2) and by Yang et al. (2013). However, no 468 
reports on their application to biosensing have been published so far.  469 
 470 
 471 
Future perspectives and conclusions 472 
 473 
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Recent work on the development of PSA aptasensors has enabled the transition from 474 
using antibody to aptamers as a recognition layer. Surface modification plays an important 475 
role in the development of promising biosensors which would be aided with the ongoing 476 
revolution in fabrication techniques. Easier fabrication would enable these biosensors to be 477 
mass produced and commercially viable. The inclination towards the development of 478 
aptasensors for PSA still needs further investigation for its use as an alternative to antibodies. 479 
Also, the sensitivity of an aptasensor is most likely to be influenced not only by the surface 480 
chemistry but also by the analytical method used for the detection of the target molecule, and 481 
so far no aptasensors have yet been used in complex samples such as blood. Overall, the 482 
development of aptamer based biosensor will see increasing reported literature because of its 483 
ease of synthesis and the possibilities of multiple modifications; it will always be a fresh field 484 
for more scope of adaptation of methodologies that will finally drive their solicitations with 485 
real blood samples. For early diagnosis of PCa, detection of different biomarkers would be 486 
preferred; consequently, more work is expected on development of aptamers for different 487 
isoforms of PSA and other biomarkers of PCa. An ideal biosensor for PCa detection would be 488 
based on a parallel sensing of different biomarkers using an array of sensors for more accurate 489 
diagnosis. In addition to the need for a simple surface chemistry, the scope of biosensor in 490 
future point-of-care devices will majorly depend on the integration of the format into a device 491 
that will enable easy and simple sample handling and an efficient read out system with rapid 492 
and accurate sample analysis of minimal blood sample volumes. 493 
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